Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Atomoxetine effects on executive function as measured by the BRIEF--a in young adults with ADHD: a randomized, double-blind, placebo-controlled study.

Adler LA, Clemow DB, Williams DW, Durell TM.

PLoS One. 2014 Aug 22;9(8):e104175. doi: 10.1371/journal.pone.0104175. eCollection 2014.

2.

Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study.

Adler L, Tanaka Y, Williams D, Trzepacz PT, Goto T, Allen AJ, Escobar R, Upadhyaya HP.

J Clin Psychopharmacol. 2014 Aug;34(4):461-6. doi: 10.1097/JCP.0000000000000138.

PMID:
24977716
3.

Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.

Durell TM, Adler LA, Williams DW, Deldar A, McGough JJ, Glaser PE, Rubin RL, Pigott TA, Sarkis EH, Fox BK.

J Clin Psychopharmacol. 2013 Feb;33(1):45-54. doi: 10.1097/JCP.0b013e31827d8a23. Erratum in: J Clin Psychopharmacol. 2014 Aug;34(4):542-3.

PMID:
23277268
4.

Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.

Adler LA, Dirks B, Deas PF, Raychaudhuri A, Dauphin MR, Lasser RA, Weisler RH.

J Clin Psychiatry. 2013 Jul;74(7):694-702. doi: 10.4088/JCP.12m08144.

PMID:
23945447
5.

Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.

Wietecha L, Williams D, Shaywitz S, Shaywitz B, Hooper SR, Wigal SB, Dunn D, McBurnett K.

J Child Adolesc Psychopharmacol. 2013 Nov;23(9):605-13. doi: 10.1089/cap.2013.0054. Epub 2013 Nov 9.

6.

Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.

Lee SI, Song DH, Shin DW, Kim JH, Lee YS, Hwang JW, Park TW, Yook KH, Lee JI, Bahn GH, Hirata Y, Goto T, Takita Y, Takahashi M, Lee S, Treuer T.

Asia Pac Psychiatry. 2014 Dec;6(4):386-96. doi: 10.1111/appy.12160. Epub 2014 Oct 27.

PMID:
25345739
8.

Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology.

Wehmeier PM, Schacht A, Ulberstad F, Lehmann M, Schneider-Fresenius C, Lehmkuhl G, Dittmann RW, Banaschewski T.

J Clin Psychopharmacol. 2012 Oct;32(5):653-60.

PMID:
22926599
9.

Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.

Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Trzepacz PT, Williams DW, Kelsey D.

J Clin Psychopharmacol. 2009 Feb;29(1):44-50. doi: 10.1097/JCP.0b013e318192e4a0.

PMID:
19142107
10.

A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.

Ni HC, Shang CY, Gau SS, Lin YJ, Huang HC, Yang LK.

Int J Neuropsychopharmacol. 2013 Oct;16(9):1959-73. doi: 10.1017/S1461145713000357. Epub 2013 May 14.

PMID:
23672818
11.

Effect of atomoxetine on executive function impairments in adults with ADHD.

Brown TE, Holdnack J, Saylor K, Adler L, Spencer T, Williams DW, Padival AK, Schuh K, Trzepacz PT, Kelsey D.

J Atten Disord. 2011 Feb;15(2):130-8. doi: 10.1177/1087054709356165. Epub 2009 Dec 21.

PMID:
20026871
12.

A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.

Harfterkamp M, van de Loo-Neus G, Minderaa RB, van der Gaag RJ, Escobar R, Schacht A, Pamulapati S, Buitelaar JK, Hoekstra PJ.

J Am Acad Child Adolesc Psychiatry. 2012 Jul;51(7):733-41. doi: 10.1016/j.jaac.2012.04.011. Epub 2012 May 25.

PMID:
22721596
13.

Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.

Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A; LYCY Study Group.

Eur Neuropsychopharmacol. 2009 Nov;19(11):822-34. doi: 10.1016/j.euroneuro.2009.07.008. Epub 2009 Aug 28.

PMID:
19716683
14.

Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.

Simpson D, Plosker GL.

CNS Drugs. 2004;18(6):397-401. Review.

PMID:
15089111
15.

Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.

Adler LA, Wilens T, Zhang S, Dittmann RW, D'Souza DN, Schuh L, Durell TM.

Clin Ther. 2012 Feb;34(2):363-73. doi: 10.1016/j.clinthera.2011.12.015. Epub 2012 Jan 27.

PMID:
22285724
16.

Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.

Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C; 31001074-ATT2001 Study Investigators.

CNS Drugs. 2012 May 1;26(5):421-34. doi: 10.2165/11631990-000000000-00000.

PMID:
22519922
17.

Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine.

Gau SS, Shang CY.

Int J Neuropsychopharmacol. 2010 Mar;13(2):243-56. doi: 10.1017/S1461145709990836. Epub 2009 Oct 23.

PMID:
19849892
18.

Differential effects of atomoxetine on executive functioning and lexical decision in attention-deficit/hyperactivity disorder and reading disorder.

de Jong CG, Van De Voorde S, Roeyers H, Raymaekers R, Allen AJ, Knijff S, Verhelst H, Temmink AH, Smit LM, Rodriques-Pereira R, Vandenberghe D, van Welsen I, ter Schuren L, Al-Hakim M, Amin A, Vlasveld L, Oosterlaan J, Sergeant JA.

J Child Adolesc Psychopharmacol. 2009 Dec;19(6):699-707. doi: 10.1089/cap.2009.0029.

PMID:
20035588
19.

Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia.

Martenyi F, Zavadenko NN, Jarkova NB, Yarosh AA, Soldatenkova VO, Bardenstein LM, Kozlova IA, Neznanov NG, Maslova OI, Petrukhin AS, Sukchotina NK, Zykov VP.

Eur Child Adolesc Psychiatry. 2010 Jan;19(1):57-66. doi: 10.1007/s00787-009-0042-7. Epub 2009 Jul 1.

PMID:
19568826
20.

Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.

Simpson D, Plosker GL.

Drugs. 2004;64(2):205-22. Review.

PMID:
14717619
Items per page

Supplemental Content

Write to the Help Desk